Name | Relationship | Address | Signature | Signature date | CIK |
---|---|---|---|---|---|
Landon Kristen | Chief Operating Officer | C/O 60 DEGREES PHARMACEUTICALS, INC., 1025 CONNECTICUT AVENUE NW SUITE 1000, WASHINGTON | /s/ Kristen Landon | 2025-08-14 | 0002053910 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | SXTP | Stock Options (Right to Buy) | Award | $0 | +4.17K | $0.00 | 4.17K | Sep 26, 2024 | Common Stock | 4.17K | $6.85 | Direct | F1, F2, F3 |
Id | Content |
---|---|
F1 | The options were granted pursuant to the 60 Degrees Pharmaceuticals, Inc. 2022 Equity Incentive Plan. The options shall vest and become exercisable in five equal tranches on the last date of each fiscal year, with the first vesting date being December 31, 2024. The options have a maximum term of 10 years from the date of grant. |
F2 | This Form 4 is being filed late due to an inadvertent administrative error. |
F3 | All information has been retroactively adjusted to reflect the 1-for-5 reverse stock split effected by the Issuer on February 24, 2025. |